Basilea Presents New Research Data On BAL27862

Basilea has presents new research data on its anti-tumor drug candidate BAL27862 at the international conference on Molecular Targets and Cancer Therapeutics in Boston (MA).

The new data suggest that BAL27862 has the potential for a distinct anticancer profile in a wide range of cancer types, including those resistant to current treatment options.

BAL27862 is a new intravenous and orally bioavailable small molecule with action against microtubules, a well established intracellular target in oncology. BAL27862 targets tumor cells by disrupting the microtubule scaffold, which is essential for cell division.

Preclinical activity has been shown against a broad range of tumor types as well as in tumor models known to be unresponsive to standard therapeutics, including marketed microtubule-targeting agents such as the taxanes. The properties of BAL27862 allow intravenous administration in the absence of solubilising excipients that are known to be associated with side effects.